Ipca Laboratories shares fall 2.11%; stock among top losers on Nifty Midcap 150

Disclaimer This is an AI-assisted live blog with updates from multiple sources Disclaimer

At previous close, the Sensex was up 266.47 points (0.32 percent) at 83,580.4, and the Nifty was up 50.90 points (0.20 percent) at 25,693.7

Shares of Ipca Laboratories declined by 2.11% to Rs 1,421.40 on Tuesday. The stock is among the top losers on the Nifty Midcap 150 index. At 3:27 pm, Ipca Laboratories was trading lower.

Financial Performance:

Consolidated Quarterly Data:

The consolidated quarterly revenue for Ipca Laboratories has shown fluctuations over the past year. Revenue for September 2024 stood at Rs 2,354.90 Crore, which decreased to Rs 2,245.37 Crore in December 2024 and slightly increased to Rs 2,246.69 Crore in March 2025. It further rose to Rs 2,308.85 Crore in June 2025 and reached Rs 2,556.50 Crore in September 2025. The net profit followed a similar trend, with Rs 245.44 Crore in September 2024, Rs 277.33 Crore in December 2024, a significant drop to Rs 65.78 Crore in March 2025, then rising to Rs 234.42 Crore in June 2025, and Rs 283.50 Crore in September 2025. Earnings per share (EPS) also varied, from Rs 9.05 in September 2024 to Rs 9.78 in December 2024, Rs 2.67 in March 2025, Rs 9.19 in June 2025, and Rs 12.35 in September 2025.

Consolidated Yearly Data:

The consolidated yearly revenue for Ipca Laboratories has increased consistently from Rs 5,419.99 Crore in 2021 to Rs 8,939.59 Crore in 2025. Net profit has fluctuated, with Rs 1,148.84 Crore in 2021, decreasing to Rs 910.95 Crore in 2022, Rs 491.93 Crore in 2023, and then increasing to Rs 529.21 Crore in 2024 and Rs 787.53 Crore in 2025. EPS has also varied, from Rs 45.01 in 2021 to Rs 35.14 in 2025. Book Value Per Share (BVPS) was Rs 371.79 in 2021 and decreased to Rs 273.88 in 2025. The Return on Equity (ROE) was 24.24% in 2021 and 10.61% in 2025. Debt to Equity ratio has remained relatively stable, with 0.05 in 2021 and 0.19 in 2025.

Ipca Laboratories' annual income statement shows consistent growth in sales, from Rs 5,419 Crore in March 2021 to Rs 8,939 Crore in March 2025. Other income has fluctuated, and total income has increased from Rs 5,482 Crore to Rs 9,032 Crore. Total expenditure has risen from Rs 4,084 Crore to Rs 7,816 Crore, and EBIT has varied, reaching Rs 1,216 Crore in March 2025. Interest expenses have shown fluctuations, and net profit has increased from Rs 1,148 Crore to Rs 787 Crore over the same period.

The quarterly income statement reveals that sales have grown from Rs 2,354 Crore in September 2024 to Rs 2,556 Crore in September 2025. Other income, total income, and total expenditure have also seen changes. EBIT has varied, and net profit has increased from Rs 245 Crore to Rs 283 Crore.

The cash flow statement indicates that cash flow from operating activities has fluctuated, while investing activities have generally involved cash outflow. Financing activities have shown variability, and the net cash flow has also changed over the years.

The balance sheet shows that total liabilities have increased from Rs 6,068 Crore in March 2021 to Rs 11,760 Crore in March 2025. Total assets have also increased from Rs 6,068 Crore to Rs 11,760 Crore during the same period.

Key financial ratios for Ipca Laboratories show a basic EPS of Rs 35.14 and a diluted EPS of Rs 29.08 as of March 2025. The book value per share was Rs 273.88. The company's debt to equity ratio was 0.19 as of March 2025.

Corporate Actions:

Ipca Laboratories announced the commencement of commercial production at the company's new manufacturing unit in Hingani, Wardha. The company held a concall to discuss the Q3FY26 results. The Board of Directors will meet on February 13, 2026, to consider and approve the standalone and consolidated unaudited financial results for the third quarter and nine months ended December 31, 2025.

The company has announced several dividends. A final dividend of Rs 2.00 per share was announced on May 29, 2025, with an effective date of August 5, 2025. Another interim dividend of Rs 2.00 per share was announced on October 24, 2024, with an effective date of November 25, 2024. The company issued a bonus share with a ratio of 1:1, and the ex-bonus date was January 28, 2005.

Ipca Laboratories had a stock split on January 10, 2022, where the old face value of Rs 2 was split into a new face value of Rs 1.

The stock is a constituent of the Nifty Midcap 150 index.